Drug Profile

APS 002

Alternative Names: APS-002; APS002 diabody - Anaeropharma; DBERB1

Latest Information Update: 28 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Anaeropharma Science
Class Antibodies; Antineoplastics; Gene therapies
Mechanism of Action T-cell receptor gene stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

No development reported Solid tumours

Most Recent Events

28 Jul 2024 No recent reports of development identified for preclinical development in Solid-tumours in Japan (IV)
22 Jun 2020 APS 002 is available for licensing as of 30 Jul 2020. http://www.anaeropharma.co.jp/partnering/ (Anaeropharma website, July 2020)
22 Jun 2020 Preclinical trials in Solid tumours in Japan (Parenteral) before June 2020

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com